Latanoprost and cystoid macular edema: Is there a causal relation?

Current Opinion in Ophthalmology

Volumn 11, Issue 2, 2000, Pages 94-100

  Schumer, Robert A ^a,d   Camras, Carl B ^b   Mandahl, Agneta K ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; PLACEBO;

BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TISSUE LEVEL; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK FACTOR;

EID: 0034023614     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200004000-00005     Document Type: Review

References (70)

1. Astin M, Stjernschantz J, Selén G: Role of nitric oxide in PGF2a-induced ocular hyperemia. Exp Eye Res 1994, 59:401-407.
2. Astin M, Stjernschantz J: Mediation of prostaglandin F2a-induced ocular surface hyperemia by sensory nerves in rabbits. Curr Eye Res 1997, 16:886-890.
3. Astin M: Effects of prostaglandin E2, F2a, and latanoprost acid on isolated ocular blood vessels in vitro. J Ocul Pharmacol Ther 1998, 14:119-128.
4. Eakins KE: Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res 1977, 25:483-498.
5. Bito LZ: Prostaglandins. Old concepts and new perspectives. Arch Ophthalmol 1987, 105:1036-1039.
6. Toris CB, Camras CB, Yablonski ME, Brubaker RF: Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997, 41:S69-S75.
7. Hoyng PFJ, Rulo AH, Greve EL, Astin M, Gjotterberg M: Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity, a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997, 41:S83-S88.
8. Toris CB, Camras CB, Yablonski ME: Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993, 100:1297-1304.
9. Lindén C, Nuija E, Alm A: Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997, 81:370-372.
10. Diestelhorst M, Roters S, Krieglstein GK: The effect of latanoprost (PHXA41) on the intraocular pressure and aqueous humor protein concentration. A randomized, double masked comparison of 50 mg/ml vs 15 mg/ml with timolol 0.5% as control. Invest Ophthalmol Vis Sci 95, 36:S823.
11. Hotehama Y, Mishima HK: Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2a-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993, 37:259-269.
12. Avakian A, Renier SA, Butler PJ: Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998, 116:679-680.
13. Ayyala RS, Cruz DA, Margo CE, Harman LE, Pautler SE, Misch DM, et al.: Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998, 126:602-604.
14. Callanan D, Fellman RL, Savage JA: Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998, 126:134-135.
15. Gaddie IB, Bennett DW: Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998, 69:122-128.
16. Heier JS, Steinert RF, Frederick AR: Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998, 116:680-682.
17. Reis A, Althaus C, Sundmacher R: Latanoprost (Xalatan) induziertes Makulaodem. Klin Monatsbl Augenheilkd 1998, 213:63-64.
18. Rowe JA, Hattenhauer MG, Herman DC: Adverse side effects associated with latanoprost. Am J Ophthalmol 1997, 124:683-685.
19. Thorne JE, Maguire AM, Lanciano R: CME and anterior uveitis with latanoprost use. Ophthalmology 1998, 105:1981-1983.
20. Wardrop DR, Wishart PK: Latanoprost and cystoid macular oedema in a pseudophake. Br J Ophthalmol 1998, 82:843-844.
21. Warwar RE, Bullock JD, Ballal D: Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review. Ophthalmology 1998, 105:263-268.
22. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, et al.: Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999, 106:1024-1029.
23. Weisz JM, Bressler NM, Bressler SB, Schachat AP: Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999, 106:1656-1659.
24. Powe NR, Schein OD, Gieser SC, Tielsch JM, Luthra R, Javitt J, Steinberg EP, for The Cataract Patient Outcome Research Team: Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Arch Ophthalmol 1994, 112:239-252.
25. Stark WJ, Worthen DM, Holladay JT, Bath PE, Jacobs ME, Murray GC, et al.: The FDA report on intraocular lenses. Ophthalmology 1983, 90:311-317.
26. Steinert RF, Puliafito CA, Kumar SR, Dudak SD, Patel S: Cystoid macular edema, retinal detachment, and glaucoma after Nd:YAG laser posterior capsulotomy. Am J Ophthalmol 1991, 112:373-380.
27. Camras CB: CME and anterior uveitis with latanoprost use. Ophthalmology 1998, 105:1978-1981.
28. Toris CB, Camras CB: Prostaglandins. A new class of aqueous outflow agents. In: Singh K, Zimmerman T, eds. J Ophthalmology Clinics of North America. Philadelphia: W.B. Saunders Co.; 1997:335-355.
29. Camras CB, Bito LZ, Toris CB: Prostaglandins and prostaglandin analogues. In: Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven; 1997:315-328.
30. Camras CB, Bito LZ, Eakins KE: Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 1977, 16:1125-1134.
31. Lee P-Y, Podos SM, Severin CH: Effect of prostaglandin F2a on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci 1984, 25:1087-1093.
32. Bito LZ: Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp Eye Res 1984, 39:807-829.
33. Bhattacherjee P, Hammond B, Salmon JA, Eakins KE: Effect of lipoxygenase products on leukocyte accumulation in the rabbit eye. Adv Prostaglandin Thromboxane Leukot Res 1982, 9:325-330.
34. Camras CB, Bhuyan KC, Podos SM, Bhuyan DK, Master RWP: Multiple dosing of prostaglandin F2a or epinephrine on cynomolgus monkey eyes. II. Slitlamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci 1987, 28:921-926.
35. Camras CB, Friedman AH, Rodrigues MM, Tripathi BJ, Tripathi RC, Podos SM: Multiple dosing of prostaglandin F 2a or epinephrine on cynomolgus monkey eyes. III. Histopathology. Invest Ophthalmol Vis Sci 1988, 29:1428-1436.
36. Tso MOM, Shih C-Y: Experimental macular edema after lens extraction. Invest Ophthalmol Vis Sci 1977, 16:381-392.
37. Flach AJ, Stegman RC, Graham J, Kruger LP: Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990, 97:1253-1258.
38. Flach AJ, Jampol LM, Weinberg D, Kraff MC, Yannuzzi LA, Campo RV, et al.: Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991, 112:514-519.
39. Flach AJ: Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992, 36:259-284.
40. Rossetti L, Chaudhuri J, Dickersin K: Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. Ophthalmology 1998, 105: 397-405.
41. Mishima HK, Masuda K, Miyake K: The putative role of prostaglandins in cystoid macular edema. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R. Liss, Inc.; 1989: 251-264.
42. Miyake K, Shirasawa E, Hikita M: Hypotheses on the role of prostaglandins in the pathogenesis of epinephrine maculopathy and aphakic cystoid macular edema. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R. Liss, Inc.; 1989:265-276.
43. Camras CB, Podos SM: The role of endogenous prostaglandins in clinically-used and investigational glaucoma therapy. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R. Liss, Inc.; 1989:459-475.
44. Roy AC, Warren BY: Inhibition of cAMP phosphodiesterase by disodium cromoglycate. Biochem Pharmacol 1974, 23:917-920.
45. Dinnendahl V, Peters HD, Schönhöfer PS: Effects of sodium salicylate and acetylsalicylic acid on cyclic 3′,5′-AMP-dependent protein kinase. Biochem Pharmacol 1973, 22:2223-2228.
46. Northover BJ: Effect of anti-inflammatory drugs on the binding of calcium to cellular membranes in various human and guinea-pig tissues. Br J Pharmacol 1973, 48:496-504.
47. Flach AJ: Nonsteroidal anti-inflammatory drugs. In: Tasman W, Jaeger EA, eds. Duane's Biomedical Foundations of Ophthalmology, volume 3. Philadelphia: J.B. Lippincott; 1994:1-32.
48. Bito LZ: A physiological approach to glaucoma management: the use of local hormones and the pharmacokinetics of prostaglandin esters. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R. Liss, Inc.; 1989:329-347.
49. Bito LZ: Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997, 41:S1-S14.
50. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S: Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999, 117:34-40.
51. Camras CB: Latanoprost may trigger the biosynthesis of endogenous prostaglandins in early postoperative pseudophakias. Arch Ophthalmol 1999, 117:1265-1266.
52. Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
53. Woodward DF, Regan JW, Lake S, Ocklind A: The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997, 41:S15-S21.
54. Villumsen J, Alm A: Prostaglandin F2a-isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol 1989, 73:419-426.
55. Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ: Maintained reduction of intraocular pressure by prostaglandin F2a-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989, 96:1329-1337.
56. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group: Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995, 102:1743-1752.
57. Watson P, Stjernschantz J, the Latanoprost Study Group: A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996, 103:126-137.
58. Camras CB, the United States Latanoprost Study Group: Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996, 103:138-147.
59. Stjernschantz J, Alm A: Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol 1996, 7:11-17.
60. Bito LZ: Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro. J Physiol Lond 1972, 221:371-387.
61. Bito LZ: Comparative study of concentrative prostaglandin accumulation by various tissues of mammals and marine vertebrates and invertebrates. Comp Biochem Physiol A 1972, 43:65-82.
62. Bito LZ: Absorptive transport of prostaglandins from intraocular fluids to blood: a review of recent findings. Exp Eye Res 1973, 16:299-306.
63. Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S: The ocular effects of prostaglandins and the therapeutic potential of a new PGF2a analog, PHXA41 (latanoprost), for glaucoma management. J Lipid Mediat 1993, 6: 535-543.
64. Sjöquist B, Almegàrd B, Khalifeh V, Alm A: The bioavailability of Xalatan in the human eye. Invest Ophthalmol Vis Sci 1997, 38:S248.
65. Sjöquist B, Tajallaei S, Stjernschantz J: Pharmacokinetics of latanoprost in the cynomolgus monkey, 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung 1999, 49:225-233.
66. Sjöquist B, Johansson A, Stjernschantz J: Pharmacokinetics of latanoprost in the cynomolgus monkey, 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung 1999, 49:240-249.
67. Rulo AH, Hoyng PFJ: Author's reply to reduction of IOP with latanoprost. Ophthalmology 1997, 104:896-897.
68. Peyman GA, Bennett TO, Vlchek J: Effects of intravitreal prostaglandins on retinal vasculature. Ann Ophthalmol 1975, 7:279-288.
69. Sjöquist B, Byding P, Resul B, Stjernschantz J: The systemic pharmacokinetics of latanoprost in man after intravenous and topical administration. Invest Ophthalmol Vis Sci 1994, 35:2220.
70. Sjöquist B, Basu S, Resul B, Stjernschantz J: The pharmacokinetics of latanoprost in the cynomolgus monkey. Invest Ophthalmol Vis Sci 1993, 34:932.